Rafael pharmaceuticals announces apollo613 phase i/ii clinical trial of cpi-613® (devimistat) in combination with hydroxychloroquine in patients with relapsed clear cell sarcoma begins enrollment at city of hope in duarte, calif.

Cranbury, n.j., sept. 27, 2021 (globe newswire) -- rafael pharmaceuticals, inc. (“rafael” or the “company”), a leader in the growing field of cancer metabolism-based therapeutics, announced that the phase 1 clinical trial of cpi-613® (devimistat) in combination with hydroxychloroquine in patients with clear cell sarcoma is open for enrollment. the clinical trial will begin enrolling patients at city of hope in duarte, california, with other sites across the country to quickly follow.
RFL Ratings Summary
RFL Quant Ranking